Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA378000
Max Phase: Preclinical
Molecular Formula: C47H73N7O11
Molecular Weight: 912.14
Molecule Type: Small molecule
Associated Items:
ID: ALA378000
Max Phase: Preclinical
Molecular Formula: C47H73N7O11
Molecular Weight: 912.14
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)C(C)C)[C@@H](C)O
Standard InChI: InChI=1S/C47H73N7O11/c1-6-7-8-9-10-11-15-21-38(58)52-40(30(4)55)46(63)53-39(29(2)3)44(61)54-41(31(5)56)45(62)50-36(27-33-22-24-34(57)25-23-33)43(60)49-35(20-16-17-26-48)42(59)51-37(47(64)65)28-32-18-13-12-14-19-32/h12-14,18-19,22-25,29-31,35-37,39-41,55-57H,6-11,15-17,20-21,26-28,48H2,1-5H3,(H,49,60)(H,50,62)(H,51,59)(H,52,58)(H,53,63)(H,54,61)(H,64,65)/t30-,31-,35+,36+,37+,39+,40+,41+/m1/s1
Standard InChI Key: CDTGHLYBYSXRGU-RDOWQFMTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 912.14 | Molecular Weight (Monoisotopic): 911.5368 | AlogP: 1.86 | #Rotatable Bonds: 31 |
Polar Surface Area: 298.61 | Molecular Species: ZWITTERION | HBA: 11 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.70 | CX Basic pKa: 17.64 | CX LogP: 0.61 | CX LogD: 0.61 |
Aromatic Rings: 2 | Heavy Atoms: 65 | QED Weighted: 0.05 | Np Likeness Score: 0.24 |
1. Basse N, Papapostolou D, Pagano M, Reboud-Ravaux M, Bernard E, Felten AS, Vanderesse R.. (2006) Development of lipopeptides for inhibiting 20S proteasomes., 16 (12): [PMID:16630721] [10.1016/j.bmcl.2006.03.033] |
Source(1):